Drug intelligence / Profile preview

LHT344

Development stage: Phase 1
Lead developer: Novartis
Administration: Oral

Overview

LHT344 is an investigational drug that has undergone early-phase clinical evaluation to assess its safety and pharmacokinetics in healthy subjects. The available information indicates that it was studied in a single-center, open-label trial involving both single and multiple oral doses administered to Chinese healthy volunteers[1][2]. No additional details regarding its mechanism of action, therapeutic class, or primary indication are provided in the available sources.

Beyond the preview

Go deeper on LHT344.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LHT344.

Explore the full profile